Preclinical Therapeutic Synergy of MEK1/2 and IGF1R Inhibition in RAS-driven Rhabdomyosarcoma

M. Yohe,X. Wan,J. Roth,K. Isanogle,C. Robinson,X. Liu,J. Chen,M. Hall,S. Difilippantonio,J. Khan

DOI: https://doi.org/10.1016/s0959-8049(20)31204-1

IF: 10.002

2020-01-01

European Journal of Cancer

Abstract:Background: Several pediatric solid tumors, such as rhabdomyosarcoma (RMS) and neuroblastoma (NB) are driven by alterations in the RAS/MAP kinase pathway and are partially responsive to MEK inhibition. Overexpression of the IGF1R as well as its ligands has been observed in multiple malignancies, including pediatric sarcomas and NB. Preclinical and clinical studies have suggested that IGF1R is itself an important target in these diseases. Previous studies revealed preclinical efficacy of the MEK1/2 inhibitor, trametinib, and an inhibitor of IGF1R, BMS75807, in cell line xenograft models of RAS-mutated RMS; however, clinical translation of this combination was limited by toxicity. Here, we sought to identify a combination of a MEK1/2 inhibitor and IGF1R inhibitor that would be better tolerated.